Introduction
In Western societies, the most prevalent cancer in men is prostate cancer. 1 The majority of prostate cancers are indolent. Only a small subset is highly aggressive and requires treatment. 2, 3 Gleason grade and tumor extent on biopsies, prostate-specific antigen (PSA) levels, and clinical stage are established preoperative prognostic parameters. These parameters are statistically powerful in retrospective analysis but insufficient for optimal individual treatment decisions. The hope is that a further understanding of disease biology will identify additional clinically applicable molecular markers for more reliable predictions of prostate cancer aggressiveness.
Centromere protein F (CENPF, also known as mitosin) is a microtubule-associated protein involved in mitosis and cell differentiation. 4 CENPF becomes upregulated during the G2/M phase and accumulates to the kinetochore complex, facilitating microtubule attachment and chromosome segregation. 5, 6 In addition, CENPF is essential -and probably rate limiting -for cell proliferation as it interacts with key 12 hepatocellular carcinoma, 13 esophageal squamous cell carcinoma, 14 gastrointestinal stromal tumors, 15 and non-Hodgkin's lymphoma, 16 and in some cases it is associated with aggressive tumor phenotype and poor survival. 11, 12, 14 Aytes et al showed that in prostate cancer cosilencing of the fork head box protein M1 (FOXM1) and CENPF abrogates tumor cell growth. 10 Zhuo et al described higher CENPF expression in 99 cancer samples compared with normal tissue and suggested an association with unfavorable tumor phenotype and poor prognosis. 17 Similar results were mentioned for the outcome of 821 patients with prostate cancers. 10 These promising data encouraged us to interrogate the prognostic impact of CENPF protein expression in a large set of prostate cancers. Therefore, we performed immunohistochemical analysis of CENPF protein expression on a panel of >11,000 prostate cancer specimens associated with follow-up information and an attached molecular database.
Materials and methods Patients
The 12,427 radical prostatectomy specimens were from patients who had surgery between 1992 and 2014 at the Department of Urology and the Martini Clinic at the University Medical Center Hamburg-Eppendorf. The specimens were analyzed according to a standard procedure. 18 Tumor stage, Gleason grade, nodal status, and status of the resection margin were retrieved from the patients' records. Quantitative Gleason grading was performed using the percentage of Gleason 4 patterns. 19 Follow-up data were available for 11,665 patients with a median follow-up of 50 months (range: 1-264 months; Table 1 ). PSA values were measured following surgery, and PSA recurrence was defined as a postoperative PSA of 0.2 ng/mL and increasing in subsequent measurements. The tissue microarray manufacturing process was described in detail earlier. 20 In short, a single 0.6 mm core was taken from a representative tissue block. For internal control, various control tissues and normal prostate tissue were included. The molecular database attached to this tissue microarray contains results on erythroblast transformation-specific (ETS)-related gene (ERG) protein expression, 21 ERG rearrangement analysis by fluorescence in situ hybridization (FISH) 22 26 cancers. The use of leftover archived diagnostic tissues for the manufacturing of tissue microarrays and their analysis in conjunction with anonymized patient data for research purposes was approved by local laws (HmbKHG, §12,1) and by the local ethics committee (Ethics commission Hamburg, WF-049/09 and PV3652). All work was carried out in compliance with the Helsinki Declaration. Figure 2 ). It is of note that ERG expression was not associated with the prognosis as indicated by identical Kaplan-Meier curves for PSA recurrence-free survival in the ERG-negative and ERG-positive subset ( Figure S1 ).
association with tumor phenotype
Increasing CENPF staining was linked to advanced pathological tumor stage, higher Gleason grade, and lymph node positivity (p<0.0001 each, Figure 3 ). Subset analysis of ERGnegative and ERG-positive cancers revealed that these associations were driven by the subset of ERG-negative cancers and much less by ERG-positive cancers (Tables S1 and S2 ).
association with other key genomic deletions
Earlier studies have provided evidence for distinct molecular subgroups of prostate cancers defined by TMPRSS2:ERG fusion and several genomic deletions. This includes a strong association of PTEN and 3p13 deletions with ERG positivity and of 5q21 and 6q15 deletions with ERG negativity. [23] [24] [25] [26] To study whether CENPF expression might be particularly associated with one of these genomic deletions, CENPF data were compared with preexisting findings on 10q23 (PTEN), 3p13 (FOXP1), 6q15 (MAP3K7), and 5q21 (CHD1) deletions. For tumors that were jointly analyzed, there were positive associations between CENPF overexpression and deletions of PTEN or 3p13 (p<0.0001 each), as well as negative associations between CENPF overexpression and deletions of 5q or 6q (p=0.027 and p<0.0001, respectively, Figure 4A ). These associations make intuitive sense due to the known link between these deletions and a positive ERG status (PTEN, 3p) or a negative ERG status (5q, 6q). However, subset analysis of ERG-negative and ERG-positive cancers demonstrated that CENPF overexpression was linked to PTEN deletions independent of the ERG status (p<0.0001 each, Figure 4B and C).
association with tumor cell proliferation
High-level CENPF staining was linked to accelerated cell proliferation as measured by the Ki67-labeling index (Ki67LI) obtained from an earlier study. 27 The average Ki67LI increased from 1.41 in cancers lacking CENPF expression to 3.35 in cancers with strong CENPF levels (p<0.0001, Figure 5 ). This association was also found both in ERG-negative (p<0.0001) and ERG-positive cancers (p=0.0061; data not shown). It was independent from the Gleason score as it held true in all tumor subsets with identical Gleason score ( Figure 5 ). 
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Follow-up data were available for 8,298 patients with interpretable CENPF staining on the tissue microarray. A highly significant association between strong CENPF expression and early PSA recurrence was seen in all tumors (p<0.0001, Figure 6A ) and in the subset of ERG fusion-negative cancers (p<0.0001, Figure 6B ). The prognostic impact of CENPF was less significant in ERG fusion-positive cancers 
Multivariate analyses
To evaluate whether CENPF expression can serve as a prognostic biomarker independent of the established prognostic factors (Gleason grade at biopsy, clinical stage, preoperative PSA level, Gleason grade at radical prostatectomy, pathological stage, surgical margin status, and nodal status), multivariate analyses of PSA recurrence-free survival were performed in 3 different scenarios (Table 2) . CENPF proved to be a significant independent prognostic parameter in all 3 scenarios. The HR for PSA recurrence after prostatectomy peaked at 1.23 in the preoperative scenario 1. This held true for the ERG-negative subset with the exception of scenario 3 and the ERG-positive subset with the exception of scenario 2.
Discussion
The results of our study identify CENPF as a strong and independent predictor of patient prognosis. Successful analysis of >9,000 prostate cancers by IHC revealed detectable CENPF staining in 90% of prostate cancers, including almost 40% of tumors with no more than weak staining. The fact that such low-level staining was also found in normal prostate glands as well as in stromal cells suggests that our IHC protocol was sufficiently sensitive to detect physiological expression of CENPF. However, increased CENPF expression in 50% of cancers indicates that CENPF becomes upregulated during malignant transformation in a high fraction of prostate cancers. Only one published study has previously evaluated CENPF protein expression by IHC in prostate cancer. In line with our findings, Zhuo et al reported significantly higher CENPF levels in 99 tumor samples compared with benign tissues. 17 Tumor-associated upregulation of CENPF was also found in other tumor types including esophageal cancer, hepatocellular carcinoma, nonHodgkin's lymphoma, nasopharyngeal cancer, and breast cancer. [11] [12] [13] [14] [15] [16] [17] CENPF overexpression was linked to features of aggressive and prognostically unfavorable cancers in our study, including advanced tumor stage, higher Gleason grade, presence of lymph node metastasis, accelerated cell proliferation, 
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CenPF expression in prostate cancer and early biochemical recurrence (p<0.0001 each). Our results are in line with earlier reports demonstrating an important role of CENPF for tumor cell proliferation in general and prostate cancer biology. For example, Laoukili et al identified CENPF as a direct target gene of the master cell cycle regulator FOXM1, which controls expression of many G2-specific genes and the activity of PI3K/AKT and MAPK signaling pathways. 28 More recently, cross-species regulatory network analysis described a synergistic interaction between FOXM1 and CENPF in driving prostate cancer malignancy and suggested that patients with overexpression of CENPF and FOXM1 had a particularly poor outcome. 10 High CENPF expression has also been linked to increased tumor aggressiveness and poor survival in esophageal squamous cell carcinoma as well as nasopharyngeal and breast cancer. 11, 12, 14 The molecular database attached to our tissue microarray allowed us to further study the impact of CENPF upregulation in molecularly defined subgroups of prostate cancers. About 50% of all prostate cancers carry a gene fusion linking the androgen-regulated serine protease TMPRSS2 with the ETStranscription factor ERG resulting in an androgen-related overexpression of ERG. 21, 29, 30 We found a massive upregulation of CENPF in a particularly high fraction of ERG-positive cancers. The reasons underlying this effect are not known. The CENPF promoter does not carry an ERG binding site according to the eukaryotic promoter database, 31 but it cannot be excluded that CENPF is an indirect transcriptional target of ERG. For example, global expression analyses indicate upregulation of other members of the CENP family, including CENPO, CENPL, and CENPV in ERG-positive as compared to ERG-negative prostate cancers. 32 Further evidence comes from recent work identifying a regulatory network comprising miR-101, CoupTFII, FOXM1, and CENPF, 33 which has been suggested to interfere with ERG-dependent transcription. 34 Irrespective of the reasons leading to CENPF upregulation in ERG-positive cancers, our data demonstrate that the prognostic value of CENPF was reduced in ERG-positive cancers. In previous studies, using the same tissue microarray, we identified various proteins with higher expression levels in ERG-positive than in ERG-negative prostate cancers. With several of these, the prognostic impact was substantially stronger in ERG-negative than in ERG-positive cancers. [35] [36] [37] The present study demonstrates that CENPF belongs to this type of protein. Other biomarkers were only prognostic in ERG-positive cancers. [38] [39] [40] Overall, these data suggest that tumor-relevant functions of CENPF and other proteins can become modified in an ERG-positive molecular environment. This is conceivable as ERG activation leads to substantial changes of the intracellular environment, affecting the expression of >1,600 genes. 21, 29, 30 Next to TMPRSS2:ERG fusions, chromosomal deletions represent the second most frequent type of genomic aberration in prostate cancers, occurring at frequencies of up to 40%. 32, 41 In particular, deletions of PTEN (20%), 6q (20%), 5q (10%), and 3p (10%) belong to the most prevalent genomic alterations in this disease. These are linked to either positive (PTEN, 3p) or negative ERG status (6q, 5q) and are associated with poor patient prognosis. [23] [24] [25] [26] CENPF overexpression was unequivocally linked to deletions of PTEN only, suggesting a functional relationship between these two genes. PTEN deletion is the main cause for hyperactive PI3K/AKT signaling in prostate cancer and is associated with tumor growth, progression, and poor clinical outcome. 42 In fact, a relevant functional interaction between CENPF and PI3K/AKT signaling is supported by recent functional data demonstrating that PI3K/AKT signaling was completely abrogated when CENPF was silenced, together with FOXM1, in DU145 prostate cancer cells. 10 The results of our study identify CENPF as a promising candidate for a molecular test of prostate cancer aggressiveness. Our multivariate modeling suggests that a potential clinical application could be suitable to gain prognostic information not only at pretherapeutic stages, when only needle biopsies can be assessed, but also after radical prostatectomy when more comprehensive pathological data are available. It is of note that the Gleason grade is the strongest (and least expensive) prognostic feature in prostate cancer. In a recent analysis, we demonstrated that by using the percentage of unfavorable Gleason patterns, the Gleason grading could be transformed from a categorical into a continuous variable with an even finer discrimination of prognostic subgroups. 19, 43 The prognostic impact of CENPF expression largely disap- 
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CenPF expression in prostate cancer Table 2 hR for Psa recurrence-free survival after prostatectomy of established prognostic parameter and CenPF expression Limitations of the present study are that it was a retrospective study and that CENPF testing was done on prostatectomy specimens. To cope with the heterogeneity of prostate cancer, Kaplan-Meier analysis was done on 8,032 patients, which should guarantee a reliable result for the cohort. For individual decision-making, a prospective study is needed with at least 10 replicates of biopsy specimens for each proband.
Due to its critical role in cell proliferation and its frequent expression in cancer cells, CENPF gained interest as a potential molecular target for novel anticancer therapies. To date, no clinically applicable anti-CENPF drugs are available, but initial in vitro experiments are encouraging for the development of strategies for pharmacological inhibition. For example, zoledronic acid, a nitrogen-containing bisphosphonate usually applied in bone disease, is found to cause loss of CENPF from the kinetochore complex in breast cancer cell lines by inhibition of CENPF farnesylation/activation, subsequently leading to delayed cell cycle progression and inhibition of cell proliferation. 44 Moreover, due to the putative effect of CENPF on growth pathways, including PI3K/AKT and MAPK signaling, 10 CENPF inhibitors may provide an attractive means for inactivation of these signaling pathways.
Conclusion
In summary, our study shows the prognostic value of CENPF. The strong association between CENPF upregulation and PTEN deletion supports the concept of a regulatory function of CENPF for major growth pathways, which makes it an attractive candidate for novel therapeutic approaches. 
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